Market News / Story
Rhelion Life Sciences Corp. (RHEL) Licenses PEX010 to UCSF Phase 2 Trial
·
Rhelion’s subsidiary Filament signed a licence and supply deal with UCSF to provide PEX010 (25 mg and 5 mg) for a Phase 2 psilocybin trial in methamphetamine use disorder among people with HIV, expected to start November 2026. Filament is not the trial sponsor. Material Details #DetailAI Analyst View1Licence & supply deal with UCSFValidates demand for PEX010 and expands clinical footprint at a top U.S. center.2PEX010 25 mg & 5 mg suppliedDemonstrates manufacturing…